A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding

Biopharmaceutics and Drug Disposition

Volumn 37, Issue 3, 2016, Pages 123-141

  Ye, Min ^a   Nagar, Swati ^a   Korzekwa, Ken ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

distribution volume; hepatic metabolism; physiologically based pharmacokinetic (PBPK) modeling; protein binding

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; DICLOFENAC; FELODIPINE; FENOPROFEN; FLUPHENAZINE; GLIPIZIDE; HALOPERIDOL; IBUPROFEN; ISOXICAM; KETOPROFEN; LORAZEPAM; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; OXAZEPAM; PRAZOSIN; PROMETHAZINE; PROPAFENONE; TENOXICAM; VERAPAMIL; DRUG; PLASMA PROTEIN; PROTEIN BINDING;

ACCURACY; ACIDITY; AREA UNDER THE CURVE; ARTICLE; BLOOD-TO-PLASMA RATIO; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; ELIMINATION HALF-LIFE; HEART OUTPUT; HEPATIC CLEARANCE; HUMAN; IN VITRO STUDY; INTRINSIC CLEARANCE; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONBIOLOGICAL MODEL; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PKA; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; TISSUE DISTRIBUTION; UNBOUND FRACTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; BIOLOGICAL MODEL; METABOLIC CLEARANCE RATE; METABOLISM;

BLOOD PROTEINS; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; TISSUE DISTRIBUTION;

EID: 84964285311     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1996     Document Type: Article

References (49)

1. Wilkinson GR, Shand DG,. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-390.
2. Obach RS,. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27: 1350-1359.
3. Baker M, Parton T,. Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica 2007; 37: 1110-1134. doi: 10.1080/00498250701658296.
4. Kochansky CJ, McMasters DR, Lu P, et al., Impact of pH on plasma protein binding in equilibrium dialysis. Mol Pharm 2008; 5: 438-448. doi: 10.1021/mp800004s.
5. Poulin P, Theil FP,. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 2000; 89: 16-35. doi: 10.1002/(SICI)1520-6017(200001)89:1<16::AID-JPS3>3.0.CO;2-E.
6. Rodgers T, Leahy D, Rowland M,. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94: 1259-1276. doi: 10.1002/jps.20322.
7. Rodgers T, Rowland M,. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95: 1238-1257. doi: 10.1002/jps.20502.
8. Poulin P, Theil FP,. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 2009; 98: 4941-4961. doi: 10.1002/jps.21759.
9. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ,. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002; 30: 1497-1503.
10. Ito K, Houston JB,. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 2004; 21: 785-792.
11. Poulin P, Jones RD, Jones HM, et al., PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci 2011; 100: 4125-4157. doi: 10.1002/jps.22550.
12. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA,. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35: 1766-1780. doi: 10.1124/dmd.107.015644.
13. Jones HM, Gardner IB, Collard WT, et al., Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2011; 50: 331-347. doi: 10.2165/11539680-000000000-00000.
14. Sohlenius-Sternbeck AK, Afzelius L, Prusis P, et al., Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 2010; 40: 637-649. doi: 10.3109/00498254.2010.500407.
15. Hallifax D, Foster JA, Houston JB,. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 2010; 27: 2150-2161. doi: 10.1007/s11095-010-0218-3.
16. Lau YY, Sapidou E, Cui X, White RE, Cheng KC,. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab Dispos 2002; 30: 1446-1454.
17. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y,. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001; 29: 1316-1324.
18. Poulin P, Haddad S,. Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. J Pharm Sci 2011; 100: 4501-4517. doi: 10.1002/jps.22619.
19. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP,. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13: 407-484.
20. Poulin P, Theil FP,. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 2002; 91: 129-156.
21. Fenneteau F, Poulin P, Nekka F,. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci 2010; 99: 486-514. doi: 10.1002/jps.21802.
22. Rowland M, Tozer T,. Clinical Pharmacokinetics: Concepts and Applications. Williams and Wilkins: Philadelphia, PA 2011; 502-503.
23. McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ,. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 2004; 32: 1247-1253. doi: 10.1124/dmd.104.000026.
24. Berezhkovskiy LM,. The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation. J Pharm Sci 2011; 100: 1167-1183.
25. Calvo MV, Lanao JM, Dominguezgil A,. Bioavailability of rectally administered naproxen. Int J Pharm 1987; 38: 117-122. doi: 10.1016/0378-5173(87)90106-2.
26. Patat A, Trocherie S, Thebault JJ, et al., EEG profile of intravenous zolpidem in healthy-volunteers. Psychopharmacology (Berl) 1994; 114: 138-146. doi: 10.1007/Bf02245455.
27. Hallifax D, Houston JB,. Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs. J Pharm Sci 2012; 101: 2645-2652. doi: 10.1002/jps.23202.
28. Berezhkovskiy LM, Liu N, Halladay JS,. Consistency of the novel equations for determination of hepatic clearance and drug time course in liver that account for the difference in drug ionization in extracellular and intracellular tissue water. J Pharm Sci 2012; 101: 516-518. doi: 10.1002/jps.23000.
29. Ito K, Houston JB,. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 2005; 22: 103-112.
30. Poulin P, Kenny JR, Hop CE, Haddad S,. In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. J Pharm Sci 2012; 101: 838-851. doi: 10.1002/jps.22792.
31. Lagas JS, van der Kruijssen CM, van de Wetering K, Beijnen JH, Schinkel AH,. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos 2009; 37: 129-136. doi: 10.1124/dmd.108.023200.
32. Kindla J, Muller F, Mieth M, Fromm MF, Konig J,. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos 2011; 39: 1047-1053. doi: 10.1124/dmd.110.037622.
33. Morita N, Kusuhara H, Nozaki Y, Endou H, Sugiyama Y,. Functional involvement of rat organic anion transporter 2 (Slc22a7) in the hepatic uptake of the nonsteroidal anti-inflammatory drug ketoprofen. Drug Metab Dispos 2005; 33: 1151-1157. doi: 10.1124/dmd.104.001552.
34. Pang KS, Rowland M,. Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred' model and a 'parallel tube' model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5: 625-653.
35. Gill KL, Houston JB, Galetin A,. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos 2012; 40: 825-835.
36. Grundy JS, Eliot LA, Foster RT,. Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharm Drug Dispos 1997; 18: 509-522.
37. Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C,. Pharmacokinetics of felodipine in patients with liver disease. Eur J Clin Pharmacol 1989; 36: 473-479.
38. Rubin A, Warrick P, Wolen RL, Chernish SM, Ridolfo AS, Gruber CM Jr,. Physiological disposition of fenoprofen in man. 3. Metabolism and protein binding of fenoprofen. J Pharmacol Exp Ther 1972; 183: 449-457.
39. Sattari S, Jamali F,. Involvement of the rat gut epithelial and muscular layer, and microflora in chiral inversion and acyl-glucuronidation of R-fenoprofen. Eur J Drug Metab Pharmacokinet 1997; 22: 97-101.
40. Thummel KE, O'Shea D, Paine MF, et al., Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502.
41. Jones HM, Gardner IB, Watson KJ,. Modelling and PBPK simulation in drug discovery. AAPS J 2009; 11: 155-166. doi: 10.1208/s12248-009-9088-1.
42. Leo A, Hansch C, Elkins D,. Partition coefficients and their uses. Chem Rev 1971; 71: 525-616. doi: 10.1021/Cr60274a001.
43. Blakey GE, Nestorov IA, Arundel PA, Aarons LJ, Rowland M,. Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J Pharmacokinet Biopharm 1997; 25: 277-312.
44. Lombardo F, Obach RS, Shalaeva MY, Gao F,. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 2002; 45: 2867-2876.
45. Ring BJ, Chien JY, Adkison KK, et al., PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci 2011; 100: 4090-4110. doi: 10.1002/jps.22552.
46. Kudo S, Ishizaki T,. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999; 37: 435-456. doi: 10.2165/00003088-199937060-00001.
47. Komura H, Iwaki M,. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity. Drug Metab Dispos 2005; 33: 726-732. doi: 10.1124/dmd.104.002550.
48. Tolle-Sander S, Rautio J, Wring S, Polli JW, Polli JE,. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 2003; 20: 757-764.
49. Rowland M, Peck C, Tucker G,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73. doi: 10.1146/annurev-pharmtox-010510-100540.